Remangilones A-C, new cytotoxic triterpenes from Physena madagascariensis

Journal of Natural Products

Volumn 62, Issue 3, 1999, Pages 471-476

  Deng, Yonghong ^a   Jiang, Tian Yi ^a   Sheng, Shijie ^b   Tianasoa Ramamonjy, Manoelson ^a,c   Snyder, John K ^a  

^a Boston University   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ESSD Madagascar   (Madagascar)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; REMANGILONE A; REMANGILONE B; REMANGILONE C; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG ISOLATION; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

PHYSENA MADAGASCARIENSIS;

EID: 0032941920     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np9805140     Document Type: Article

References (29)

1. Sibree, J. In A Naturalist in Madagascar, Seeley, Service, & Co.: London, 1915; p 157.
2. Morton, C. W.; Karol, K. G.; Chase, M. W. Bot. Rev. 1997, 63, 231-239.
3. Other classes of triterpenes fitting this structural requirement include the germanicanes, taraxeranes, glutinanes, and friedelanes: (a) Devon, T. K.; Scott, A. I. Handbook of Naturally Occurring Compounds, Academic: New York, 1972; Vol. II, pp 281-284.
4. (b) Nakanishi, K., Goto, T., Ito, S., Natori, S., Nozoe, S., Eds. Natural Products Chemistry; Academic Press: New York, 1974; Vol. 1, pp 315-316.
5. This rules out the taraxerane skeleton.
6. This eliminates the possibility of a glutinane or friedelane triterpene.
7. (a) Baran, J. S. J. Am. Chem. Soc. 1958, 80, 1687-1691.
8. (b) Clarke, R. L. J. Am. Chem. Soc. 1960, 82, 4629-4631.
9. Kitagawa, I.; Nakanishi, T. Chem. Pharm. Bull. 1981, 29, 1299-1311.
10. Tschesche, R.; Moerner, I.; Snatzke, G. J. Liebigs Ann. Chem. 1963, 670, 103-115.
11. 18,19 unit of unsaturation (ref 3), but the parent skeleton is formally H-18α (ref 3b). For reviews of triterpenoids, see: Mahato, S. B.; Sen, S. Phytochemistry 1997, 44, 1185-1236, and earlier reviews cited therein.
12. For a recent report of a 24,28-dinor-18α-oleanane (24,28-dinorgermanicane), see: Trendel, J. M.; Graff, R.; Albrecht, P. Tetrahedron Lett. 1991, 32, 2959-2961.
13. (a) Wehrli, F. W.; Nishida, T. Prog. Chem. Org. Nat. Prod. 1979, 36, 1-229.
14. (b) Mahato, S. B.; Kundu, A. P. Phytochemistry 1994, 37, 1517-1575.
15. (a)Tezuka, Y.; Kikuchi, T.; Dhanabalasingham, B.; Karunaratne, V.; Gunatilaka, A. A. L. Nat. Prod. Lett. 1993, 3, 273-276.
16. (b) Adelakun, E. A.; Okogun, J.; Howarth, O. W.; Matlin, S. A. Fitoterapia 1996, 68, 443-445.
17. See ref 11 also: Dhanabalasingham, B.; Karunaratne, V.; Tezuka, Y.; Kikuchi, T.; Gunatilaka, A. A. L. Phytochemistry 1996, 42, 1377-1385.
18. Pizao, P. E.; Lyaruu, D. M.; Peters, G. J.; van Ark-Otte, J.; Winograd, B.; Giaccone, G.; Pinedo, H. M. Br. J. Cancer 1992, 66, 660-665.
19. Meikrantz, W.; Gisselbrecht, S.; Tam, S. W.; Schlegel, R. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3754-3758.
20. Cohen, J. J. Immunol. Today 1993, 14, 126-130.
21. Hannun, Y. A. Blood 1997, 89, 1845-1853.
22. Further details of the studies into the biological activities of 1-3 and other related compounds will be reported in due course.
23. Gunatilaka, A. A. L. Prog. Chem. Org. Nat. Prod. 1996, 67, 1-123.
24. Liu, X. L.; Band, H.; Gao, Q.; Wazer, D. E.; Chu, Q.; Band, V. Carcinogenesis 1994, 15, 1969-1973.
25. (a) Nagasawa, H.; Li, C. Y.; Maki, C. G.; Imrich, A. C.; Little, J. B. Cancer Res. 1995, 55, 1842-1846.
26. (b) Hawkins, D. S.; Demers, G. W.; Galloway, D. A. Cancer Res. 1996, 56, 892-898.
27. Band, V.; Sager, R. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 1249-1253.
28. Band, V.; Zajchowski, D.; Swisshelm, K.; Trask, D.; Cohen, C.; Connolly, J.; Sager, R. Cancer Res. 1990, 50, 7351-7357.
29. Au, J. L.; Li, D.; Gan, Y.; Gao, X.; Johnson, A. L.; Johnston, J.; Millenbaugh, N. J.; Jang, S. H.; Kuh, H. J.; Chen, C. T.; Wientjes, M. G. Cancer Res. 1998, 58, 2141-2148.